Intezyne Technologies, a privately held oncology drug development company, has acquired Niiki Pharma. Intezyne has two compounds in early and mid-stage clinical development. Its lead candidate is a first-in-class GRP78 suppressor, which has demonstrated significant potential in patients with neuroendocrine tumors. “Niiki Pharma’s GRP78 suppressor is the leading candidate in the field against this novel target and has the potential to enhance the treatment of neuroendocrine tumors an...